ARTIA-Lung
Phase NA Withdrawn
BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases
Phase 2 Withdrawn
Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression
Phase 2 Withdrawn
Effect of N-Acetyl Cysteine (NAC) on the Oral Microbiome
Phase 2 Withdrawn
Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
Phase 2 Withdrawn
CRATER
Phase 2 Withdrawn
A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis(SHR-1210-HLJ-009)
Phase NA Withdrawn
CKPancreas
Phase 2 Withdrawn
Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers
Phase 2/3 Withdrawn
ADHERE
Phase 3 Withdrawn
Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer
Phase 2 Withdrawn
OLIVER
Phase NA Withdrawn
Proton Therapy for High Risk Prostate Cancer
Phase NA Withdrawn
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Phase 3 Withdrawn
Z0011-China
Phase 3 Withdrawn
DIACAL
Phase 2 Withdrawn
Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
Phase 2 Withdrawn
NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer
Phase 2 Withdrawn
Prometheus
Phase 4 Withdrawn
The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer
Phase 2 Withdrawn
Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
Phase 2 Withdrawn
Oncoplastic Breast-conserving Surgery in Non-metastatic Breast Cancer Patients
Withdrawn
Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer
Phase 1 Withdrawn
Outpatient Health Care Program for Older Patients Receiving Chemotherapy for Newly Diagnosed Breast Cancer or Colon Cancer
Withdrawn
Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment
Phase 1 Withdrawn
CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)
Phase 2 Withdrawn
S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer
Phase 2 Withdrawn
Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1 Withdrawn
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
Phase 2 Withdrawn
High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma
Phase 2 Withdrawn
Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma
Phase 2 Withdrawn
Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia
Phase 1/2 Withdrawn
Chemotherapy and Hormone Therapy as First-Line Therapy in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer
Phase 3 Withdrawn
Liposomal Tretinoin in Treating Patients With Recurrent or Refractory Hodgkin's Disease
Phase 2 Withdrawn